TN2009000084A1 - Adenosine derivatives as a2a receptor agonists - Google Patents

Adenosine derivatives as a2a receptor agonists

Info

Publication number: TN2009000084A1
Authority: TN; Tunisia
Prior art keywords: receptor agonists; adenosine derivatives; stereoisomers; compounds; formula
Prior art date: 2006-09-14

Application number

TN2009000084A

Other languages

English (en)

Inventor

Robin Alec Fairhurst

Roger John Taylor

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-14

Filing date

2009-03-13

Publication date

2010-08-19

2009-03-13 Application filed by Novartis Ag filed Critical Novartis Ag

2010-08-19 Publication of TN2009000084A1 publication Critical patent/TN2009000084A1/fr

Links

101150051188 Adora2a gene Proteins 0.000 title 1
150000003835 adenosine derivatives Chemical class 0.000 title 1
239000000018 receptor agonist Substances 0.000 title 1
229940044601 receptor agonist Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
150000003839 salts Chemical class 0.000 abstract 2
102000007471 Adenosine A2A receptor Human genes 0.000 abstract 1
108010085277 Adenosine A2A receptor Proteins 0.000 abstract 1
208000027771 Obstructive airways disease Diseases 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Hydrogenated Pyridines (AREA)

TN2009000084A 2006-09-14 2009-03-13 Adenosine derivatives as a2a receptor agonists TN2009000084A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP06120706A EP1903044A1 (fr)	2006-09-14	2006-09-14	Derivés de l'adénosine en tant qu' agonistes du récepteur A2A
PCT/EP2007/059666 WO2008031875A1 (fr)	2006-09-14	2007-09-13	Utilisation de dérivés de l'adénosine en tant qu'agonistes du récepteurs a2a

Publications (1)

Publication Number	Publication Date
TN2009000084A1 true TN2009000084A1 (en)	2010-08-19

Family

ID=37622170

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2009000084A TN2009000084A1 (en)	2006-09-14	2009-03-13	Adenosine derivatives as a2a receptor agonists

Country Status (31)

Country	Link
US (1)	US8188100B2 (fr)
EP (2)	EP1903044A1 (fr)
JP (1)	JP2010503639A (fr)
KR (1)	KR20090040386A (fr)
CN (1)	CN101511831B (fr)
AR (1)	AR062768A1 (fr)
AT (1)	ATE481404T1 (fr)
AU (1)	AU2007296227A1 (fr)
BR (1)	BRPI0716936A2 (fr)
CA (1)	CA2662104A1 (fr)
CL (1)	CL2007002658A1 (fr)
CR (1)	CR10621A (fr)
CY (1)	CY1110990T1 (fr)
DE (1)	DE602007009272D1 (fr)
DK (1)	DK2066669T3 (fr)
ES (1)	ES2353141T3 (fr)
HK (1)	HK1131392A1 (fr)
HR (1)	HRP20100694T1 (fr)
IL (1)	IL197153A0 (fr)
MA (1)	MA30722B1 (fr)
MX (1)	MX2009002811A (fr)
NO (1)	NO20091244L (fr)
PE (1)	PE20081151A1 (fr)
PL (1)	PL2066669T3 (fr)
PT (1)	PT2066669E (fr)
RU (1)	RU2009113668A (fr)
SI (1)	SI2066669T1 (fr)
TN (1)	TN2009000084A1 (fr)
TW (1)	TW200821324A (fr)
WO (1)	WO2008031875A1 (fr)
ZA (1)	ZA200901036B (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ545787A (en) *	2001-10-01	2007-12-21	Univ Virginia	2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
GT200500281A (es) *	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
US9512125B2 (en)	2004-11-19	2016-12-06	The Regents Of The University Of California	Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
GB0500785D0 (en)	2005-01-14	2005-02-23	Novartis Ag	Organic compounds
WO2007120972A2 (fr) *	2006-02-10	2007-10-25	University Of Virginia Patent Foundation	Procede permettant de traiter l'anemie a hematies falciformes
WO2007114926A2 (fr)	2006-04-04	2007-10-11	The Regents Of The University Of California	Antagonistes de la kinase
GB0607953D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607944D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
KR20080110925A (ko) *	2006-04-21	2008-12-19	노파르티스 아게	아데노신 ａ２ａ 수용체 효능제로서 사용하기 위한 퓨린 유도체
GB0607950D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
US8188063B2 (en)	2006-06-19	2012-05-29	University Of Virginia Patent Foundation	Use of adenosine A2A modulators to treat spinal cord injury
CA2657973A1 (fr) *	2006-06-27	2008-01-03	Biovitrum Ab (Publ)	Composes therapeutiques
EP1889846A1 (fr)	2006-07-13	2008-02-20	Novartis AG	Dérivés de purine comme agonistes du recepteur A2a
CN101553459A (zh) *	2006-11-10	2009-10-07	诺瓦提斯公司	环戊烯二醇单乙酸酯衍生物
WO2009046448A1 (fr)	2007-10-04	2009-04-09	Intellikine, Inc.	Entités chimiques et leurs utilisations thérapeutiques
US20100197914A1 (en) *	2007-10-17	2010-08-05	Robin Alec Fairhurst	Purine Derivatives as Adenosine Al Receptor Ligands
US8058259B2 (en)	2007-12-20	2011-11-15	University Of Virginia Patent Foundation	Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
DK2240451T3 (da)	2008-01-04	2017-11-20	Intellikine Llc	Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5547099B2 (ja)	2008-03-14	2014-07-09	インテリカイン，エルエルシー	キナーゼ阻害剤および使用方法
WO2009114874A2 (fr)	2008-03-14	2009-09-17	Intellikine, Inc.	Inhibiteurs de kinases (benzothiazole) et procédés d’utilisation associés
WO2010006072A2 (fr)	2008-07-08	2010-01-14	The Regents Of The University Of California	Modulateurs de mtor et leurs utilisations
WO2010006086A2 (fr)	2008-07-08	2010-01-14	Intellikine, Inc.	Inhibiteurs de kinases et procédés d'utilisation
US8703778B2 (en)	2008-09-26	2014-04-22	Intellikine Llc	Heterocyclic kinase inhibitors
ES2570429T3 (es)	2008-10-16	2016-05-18	Univ California	Inhibidores de heteroaril quinasa de anillo condensado
US8476431B2 (en)	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (ja)	2009-05-07	2015-10-07	インテリカイン，エルエルシー	複素環式化合物およびその使用
UA111579C2 (uk)	2009-08-17	2016-05-25	Інтеллікіне Ллк	ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
WO2011047384A2 (fr)	2009-10-16	2011-04-21	The Regents Of The University Of California	Procédés d'inhibition de l'activité ire1
EP2571357B1 (fr)	2010-05-21	2016-07-06	Infinity Pharmaceuticals, Inc.	Composés chimiques, compositions et procédés pour modulation de kinases
US8901133B2 (en)	2010-11-10	2014-12-02	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
TWI546305B (zh)	2011-01-10	2016-08-21	英菲尼提製藥股份有限公司	製備異喹啉酮之方法及異喹啉酮之固體形式
EP2678018A4 (fr)	2011-02-23	2015-09-30	Intellikine Llc	Combinaison d'inhibiteurs des kinases et utilisations associées
CN103930422A (zh)	2011-07-19	2014-07-16	无限药品股份有限公司	杂环化合物及其用途
TWI565709B (zh)	2011-07-19	2017-01-11	英菲尼提製藥股份有限公司	雜環化合物及其用途
AR091790A1 (es)	2011-08-29	2015-03-04	Infinity Pharmaceuticals Inc	Derivados de isoquinolin-1-ona y sus usos
JP6342805B2 (ja)	2011-09-02	2018-06-13	ザリージェンツオブザユニバーシティオブカリフォルニア	置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CA2886240A1 (fr)	2012-09-26	2014-04-03	The Regents Of The University Of California	Modulation de ire1
AU2013337717B2 (en)	2012-11-01	2018-10-25	Infinity Pharmaceuticals, Inc.	Treatment of cancers using PI3 kinase isoform modulators
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9751888B2 (en)	2013-10-04	2017-09-05	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
BR112016007467B1 (pt)	2013-10-04	2022-09-20	Infinity Pharmaceuticals, Inc	Compostos heterocíclicos e usos dos mesmos
SG11201607705XA (en)	2014-03-19	2016-10-28	Infinity Pharmaceuticals Inc	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (fr)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Polythérapies
CN105012318B (zh) *	2014-04-17	2020-02-11	沈华浩	磺酰胺类化合物在气道慢性炎症性疾病中的应用
WO2016054491A1 (fr)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Composés hétérocycliques et leurs utilisations
EP3350183B1 (fr)	2015-09-14	2025-04-02	Twelve Therapeutics, Inc.	Formes solides de dérivés d'isoquinolinone, leur procédé de fabrication, compositions les comprenant et méthodes d'utilisation de celles-ci
AU2017235462B2 (en) *	2016-03-16	2021-07-01	Kura Oncology, Inc.	Bridged bicyclic inhibitors of menin-MLL and methods of use
MX388839B (es) *	2016-03-16	2025-03-20	Kura Oncology Inc	Inhibidores sustituidos de menina-mll y metodos de uso
US10759806B2 (en)	2016-03-17	2020-09-01	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
JP7054681B2 (ja)	2016-06-24	2022-04-14	インフィニティーファーマシューティカルズ，インコーポレイテッド	組合せ療法
US11944627B2 (en)	2017-03-24	2024-04-02	Kura Oncology, Inc.	Methods for treating hematological malignancies and Ewing's sarcoma
US11542248B2 (en)	2017-06-08	2023-01-03	Kura Oncology, Inc.	Methods and compositions for inhibiting the interaction of menin with MLL proteins
WO2019060365A1 (fr)	2017-09-20	2019-03-28	Kura Oncology, Inc.	Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
RU2748993C1 (ru)	2017-09-28	2021-06-02	СиСТОУН ФАРМАСЬЮТИКАЛС (СУЧЖОУ) КО., ЛТД.	Производное с конденсированным кольцом в качестве ингибитора рецептора a2a

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1528382A (en) *	1974-12-26	1978-10-11	Teijin Ltd	Cyclopentene diols and acyl esters thereof and processes for their preparation
US4738954A (en) *	1985-11-06	1988-04-19	Warner-Lambert Company	Novel N6 -substituted-5'-oxidized adenosine analogs
US4873360A (en) *	1986-07-10	1989-10-10	Board Of Governors Of Wayne State University	Process for the preparation of cyclopentanoids and novel intermediates produced thereby
IL84414A0 (en)	1986-11-14	1988-04-29	Ciba Geigy Ag	N9-cyclopentyl-substituted adenine derivatives
US4954504A (en) *	1986-11-14	1990-09-04	Ciba-Geigy Corporation	N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity
JP2586897B2 (ja)	1987-03-09	1997-03-05	富士薬品工業株式会社	光学活性なシス−シクロペンテン−３，５−ジオ−ルモノエステルの製造法
AU654507B2 (en)	1990-09-25	1994-11-10	Rhone-Poulenc Rorer International (Holdings) Inc.	Compounds having antihypertensive and anti-ischemic properties
IT1254915B (it)	1992-04-24	1995-10-11	Gloria Cristalli	Derivati di adenosina ad attivita' a2 agonista
US5688774A (en) *	1993-07-13	1997-11-18	The United States Of America As Represented By The Department Of Health And Human Services	A3 adenosine receptor agonists
US5691188A (en) *	1994-02-14	1997-11-25	American Cyanamid Company	Transformed yeast cells expressing heterologous G-protein coupled receptor
HUP9900969A3 (en) *	1996-01-02	2001-11-28	Aventis Pharmaceuticals Inc Co	Process for preparing 2,4-dihydroxypyridine and 2,4-dihydroxy-3-nitropyridine
US6376472B1 (en) *	1996-07-08	2002-04-23	Aventis Pharmaceuticals, Inc.	Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
US6211165B1 (en) *	1997-05-09	2001-04-03	The Trustees Of The University Of Pennsylvania	Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
GB9813554D0 (en) *	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
GB9813540D0 (en)	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
BR9911482A (pt)	1998-06-23	2002-01-22	Glaxo Group Ltd	Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
GB9813535D0 (en)	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
CA2347512C (fr)	1998-10-16	2005-12-06	Pfizer Inc.	Derives d'adenine
BR9917000A (pt) *	1998-12-31	2001-12-11	Aventis Pharm Prod Inc	Processo para preparar derivados dedesaza-adenosina n6-substituìda
US7427606B2 (en) *	1999-02-01	2008-09-23	University Of Virginia Patent Foundation	Method to reduce inflammatory response in transplanted tissue
US6322771B1 (en)	1999-06-18	2001-11-27	University Of Virginia Patent Foundation	Induction of pharmacological stress with adenosine receptor agonists
US6214807B1 (en) *	1999-06-22	2001-04-10	Cv Therapeutics, Inc.	C-pyrazole 2A A receptor agonists
US6403567B1 (en)	1999-06-22	2002-06-11	Cv Therapeutics, Inc.	N-pyrazole A2A adenosine receptor agonists
US6586413B2 (en) *	1999-11-05	2003-07-01	The United States Of America As Represented By The Department Of Health And Human Services	Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
GB0003960D0 (en)	2000-02-18	2000-04-12	Pfizer Ltd	Purine derivatives
GB0022695D0 (en)	2000-09-15	2000-11-01	Pfizer Ltd	Purine Derivatives
AU2002219497B2 (en) *	2001-01-16	2004-08-26	Can-Fite Biopharma Ltd.	Use of an adenosine A3 receptor agonist for inhibition of viral replication
GB2372741A (en)	2001-03-03	2002-09-04	Univ Leiden	C2,8-Disubstituted adenosine derivatives and their different uses
US20040162422A1 (en) *	2001-03-20	2004-08-19	Adrian Hall	Chemical compounds
EP1258247A1 (fr) *	2001-05-14	2002-11-20	Aventis Pharma Deutschland GmbH	Analogues d'adénosine pour le traitement de le diabete et de la resistance à l' insuline
NZ545787A (en)	2001-10-01	2007-12-21	Univ Virginia	2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
US7414036B2 (en) *	2002-01-25	2008-08-19	Muscagen Limited	Compounds useful as A3 adenosine receptor agonists
ATE381336T1 (de)	2002-04-10	2008-01-15	Univ Virginia	Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
US7465715B2 (en) *	2003-12-29	2008-12-16	Can-Fite Biopharma, Ltd.	Method for treatment of multiple sclerosis
EA011099B1 (ru)	2004-03-05	2008-12-30	Кембридж Байотекнолоджи Лимитед	Терапевтические соединения
WO2005107463A1 (fr)	2004-05-03	2005-11-17	University Of Virginia Patent Foundation	Agonistes de recepteurs de l'adenosine a2a servant au traitement d'une nephropathie diabetique
AR049384A1 (es) *	2004-05-24	2006-07-26	Glaxo Group Ltd	Derivados de purina
US7825102B2 (en) *	2004-07-28	2010-11-02	Can-Fite Biopharma Ltd.	Treatment of dry eye conditions
JP4642847B2 (ja)	2004-07-28	2011-03-02	キャン−ファイト・バイオファーマ・リミテッド	シェーグレン症候群を含むドライアイ疾患治療用アデノシンａ３レセプターアゴニスト
BRPI0515030A (pt) *	2004-09-09	2008-07-01	Us Gov Health & Human Serv	derivados de purina como agonistas de receptor de adenosina a3 e a1
GT200500281A (es) *	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
US20080051364A1 (en) *	2004-11-08	2008-02-28	Pninna Fishman	Therapeutic Treatment of Accelerated Bone Resorption
GB0500785D0 (en)	2005-01-14	2005-02-23	Novartis Ag	Organic compounds
RS52458B (en) *	2005-02-04	2013-02-28	Millennium Pharmaceuticals Inc.	E1 ENZYMING ENZYME INHIBITORS
GB0505219D0 (en) *	2005-03-14	2005-04-20	Novartis Ag	Organic compounds
GB0514809D0 (en) *	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
CA2622879C (fr) *	2005-11-30	2011-07-05	Can-Fite Biopharma Ltd.	Utilisation de l'agoniste des recepteurs de l'adenosine a3 dans le traitement de l'osteoarthrite
JP5414277B2 (ja) *	2006-01-26	2014-02-12	ザ・ガバメント・オブ・ジ・ユナイテッド・ステイツ・オブ・アメリカ・レプリゼンテッド・バイ・ザ・セクレタリー・ディパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズ	Ａ３アデノシンレセプタ・アロステリックモジュレータ
CA2639924C (fr) *	2006-02-02	2017-01-10	Millennium Pharmaceuticals, Inc.	Inhibiteurs d'enzymes d'activation e1
WO2007092936A2 (fr) *	2006-02-08	2007-08-16	University Of Virginia Patent Foundation	Procédé pour traiter des lésions gastriques
GB0607953D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607945D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
KR20080110925A (ko)	2006-04-21	2008-12-19	노파르티스 아게	아데노신 ａ２ａ 수용체 효능제로서 사용하기 위한 퓨린 유도체
GB0607954D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607950D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607948D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607951D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607944D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
EP1889846A1 (fr) *	2006-07-13	2008-02-20	Novartis AG	Dérivés de purine comme agonistes du recepteur A2a
US8008307B2 (en) *	2006-08-08	2011-08-30	Millennium Pharmaceuticals, Inc.	Heteroaryl compounds useful as inhibitors of E1 activating enzymes
CN101553459A (zh) *	2006-11-10	2009-10-07	诺瓦提斯公司	环戊烯二醇单乙酸酯衍生物
WO2008124150A1 (fr) *	2007-04-09	2008-10-16	University Of Virginia Patent Foundation	Méthode de traitement de l'entérite, d'une lésion intestinale et de la diarrhée provoquées par des bactéries c. difficile au moyen d'un agoniste du récepteur a2a de l'adénosine
US20080262001A1 (en) *	2007-04-23	2008-10-23	Adenosine Therapeutics, Llc	Agonists of a2a adenosine receptors for treating recurrent tumor growth in the liver following resection
EP2170401A1 (fr) *	2007-06-29	2010-04-07	Government of the United States of America, Represented by the Secretary, Department of Health and Human Services	Conjugués de dendrimère d'agonistes et d'antagonistes de la superfamille des gpcr
US20100197914A1 (en) *	2007-10-17	2010-08-05	Robin Alec Fairhurst	Purine Derivatives as Adenosine Al Receptor Ligands
US20090181934A1 (en) *	2007-10-17	2009-07-16	Novartis Ag	Organic Compounds
US8183225B2 (en) *	2007-11-08	2012-05-22	New York University	Inhibition of bone resorption using medical implants containing adenosine receptor antagonists
BRPI0907248A2 (pt) *	2008-01-09	2019-02-26	Pgxhealth, Llc	tratamento intratecal de dor neuropática com agonistas a2ar

2006
- 2006-09-14 EP EP06120706A patent/EP1903044A1/fr not_active Ceased
2007
- 2007-09-12 PE PE2007001224A patent/PE20081151A1/es not_active Application Discontinuation
- 2007-09-12 AR ARP070104040A patent/AR062768A1/es not_active Application Discontinuation
- 2007-09-13 RU RU2009113668/04A patent/RU2009113668A/ru unknown
- 2007-09-13 KR KR1020097005251A patent/KR20090040386A/ko not_active Abandoned
- 2007-09-13 DE DE602007009272T patent/DE602007009272D1/de active Active
- 2007-09-13 SI SI200730448T patent/SI2066669T1/sl unknown
- 2007-09-13 CN CN2007800333258A patent/CN101511831B/zh not_active Expired - Fee Related
- 2007-09-13 DK DK07803477.4T patent/DK2066669T3/da active
- 2007-09-13 AT AT07803477T patent/ATE481404T1/de active
- 2007-09-13 AU AU2007296227A patent/AU2007296227A1/en not_active Abandoned
- 2007-09-13 PT PT07803477T patent/PT2066669E/pt unknown
- 2007-09-13 BR BRPI0716936-1A2A patent/BRPI0716936A2/pt not_active IP Right Cessation
- 2007-09-13 ES ES07803477T patent/ES2353141T3/es active Active
- 2007-09-13 WO PCT/EP2007/059666 patent/WO2008031875A1/fr active Application Filing
- 2007-09-13 TW TW096134289A patent/TW200821324A/zh unknown
- 2007-09-13 US US12/310,254 patent/US8188100B2/en not_active Expired - Fee Related
- 2007-09-13 PL PL07803477T patent/PL2066669T3/pl unknown
- 2007-09-13 JP JP2009527828A patent/JP2010503639A/ja not_active Withdrawn
- 2007-09-13 CA CA002662104A patent/CA2662104A1/fr not_active Abandoned
- 2007-09-13 MX MX2009002811A patent/MX2009002811A/es not_active Application Discontinuation
- 2007-09-13 CL CL200702658A patent/CL2007002658A1/es unknown
- 2007-09-13 EP EP07803477A patent/EP2066669B1/fr active Active
2009
- 2009-02-13 ZA ZA200901036A patent/ZA200901036B/xx unknown
- 2009-02-19 CR CR10621A patent/CR10621A/es not_active Application Discontinuation
- 2009-02-19 IL IL197153A patent/IL197153A0/en unknown
- 2009-03-13 TN TN2009000084A patent/TN2009000084A1/fr unknown
- 2009-03-25 NO NO20091244A patent/NO20091244L/no not_active Application Discontinuation
- 2009-03-30 MA MA31736A patent/MA30722B1/fr unknown
- 2009-12-03 HK HK09111343.2A patent/HK1131392A1/xx unknown
2010
- 2010-12-14 HR HR20100694T patent/HRP20100694T1/hr unknown
- 2010-12-15 CY CY20101101154T patent/CY1110990T1/el unknown

Also Published As

Publication number	Publication date
WO2008031875A1 (fr)	2008-03-20
EP2066669B1 (fr)	2010-09-15
DE602007009272D1 (de)	2010-10-28
CN101511831B (zh)	2012-04-25
CL2007002658A1 (es)	2008-08-08
PT2066669E (pt)	2010-12-17
RU2009113668A (ru)	2010-10-20
PE20081151A1 (es)	2008-10-06
ES2353141T3 (es)	2011-02-25
JP2010503639A (ja)	2010-02-04
BRPI0716936A2 (pt)	2013-09-17
NO20091244L (no)	2009-04-07
MX2009002811A (es)	2009-03-31
HRP20100694T1 (hr)	2011-01-31
SI2066669T1 (sl)	2011-01-31
ZA200901036B (en)	2010-01-27
CR10621A (es)	2009-03-27
CN101511831A (zh)	2009-08-19
US8188100B2 (en)	2012-05-29
TW200821324A (en)	2008-05-16
AR062768A1 (es)	2008-12-03
DK2066669T3 (da)	2011-01-10
KR20090040386A (ko)	2009-04-23
CA2662104A1 (fr)	2008-03-20
EP1903044A1 (fr)	2008-03-26
CY1110990T1 (el)	2015-06-11
US20090325967A1 (en)	2009-12-31
PL2066669T3 (pl)	2011-03-31
HK1131392A1 (en)	2010-01-22
MA30722B1 (fr)	2009-09-01
EP2066669A1 (fr)	2009-06-10
ATE481404T1 (de)	2010-10-15
AU2007296227A1 (en)	2008-03-20
IL197153A0 (en)	2009-11-18

Publication	Publication Date	Title
TN2009000084A1 (en)	2010-08-19	Adenosine derivatives as a2a receptor agonists
TNSN07268A1 (en)	2008-12-31	Purine derivatives acting as a2a receptor agonists
TNSN08544A1 (en)	2010-04-14	Purine derivatives as a2a agonists
MY146645A (en)	2012-09-14	Purine derivatives for use as adenosin a2a receptor agonists
PT2012759E (pt)	2010-04-19	Derivados de purina como agonistas do receptor a2a
TNSN07154A1 (en)	2008-11-21	Purine derivatives for use as adenosin a-2a receptor agonists
WO2007121921A3 (fr)	2008-01-10	Composés organiques
MX2008016134A (es)	2009-01-15	Derivados de fenol para el tratamiento de enfermedades respiratorias.
NO20072371L (no)	2007-07-12	Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
TN2010000167A1 (en)	2011-11-11	Organic compounds
AU2015221439B2 (en)	2016-07-14	Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same
GEP20105074B (en)	2010-09-10	Pyrimidinyl aryl urea derivatives being fgf inhibitors
MX2009011802A (es)	2009-11-18	Imidazoquinolinas con propiedades inmunomoduladoras.
MX2009000169A (es)	2009-01-26	Derivados de purinona como agonistas de hm74a.
TW200738729A (en)	2007-10-16	Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
PH12012501800A1 (en)	2012-12-10	2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
MX2009003739A (es)	2009-09-04	Derivados de hidrobenzamida como inhibidores de hsp90.
NO20092058L (no)	2009-09-17	Heteroaryl pyrrolidinyl ketonderivater
ATE490958T1 (de)	2010-12-15	Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
GB0417910D0 (en)	2004-09-15	Organic compounds
TNSN08369A1 (en)	2009-12-29	Benzimidazole derivatives
NZ612920A (en)	2015-10-30	Process of making gyrase and topoisomerase iv inhibitors
MY156955A (en)	2016-04-15	Antifungal agents
NO20090421L (no)	2009-02-06	Arylpiperazinderivater og deres anvendelse
MX2010008778A (es)	2010-08-30	Derivados de 3-alquil-piperazina y usos de la misma.